Compugen Ltd. CGEN

Company Overview

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on immuno-oncology. The company applies proprietary computational biology and predictive discovery platforms to identify novel immune checkpoint regulators and drug targets, primarily for cancer treatment. Compugen operates at the intersection of biotechnology, drug discovery, and artificial intelligence–driven biology, with its core value proposition centered on uncovering previously unknown biological mechanisms that can be translated into first-in-class therapeutics.

Founded in 1993, Compugen initially focused on computational genomics before strategically pivoting in the mid-2000s toward immunology and oncology as these fields matured. The company’s evolution has been marked by the development of internally discovered immune targets and advancement into clinical-stage programs. Compugen is publicly traded on NASDAQ under the ticker CGEN and has positioned itself as a discovery-driven partner to larger pharmaceutical companies.